---
title: "SVRA: MOLBREEVI shows strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295577539.md"
description: "MOLBREEVI, an inhaled biologic for autoimmune PAP, demonstrated significant clinical benefits and a favorable safety profile in Phase 3 trials, addressing a high unmet need in a rare disease with no approved therapies. Regulatory filings are underway, with a potential U.S. market exceeding $2B and robust financial backing.Original document: Savara, Inc. [SVRA] Slides Release — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-11T20:34:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295577539.md)
  - [en](https://longbridge.com/en/news/295577539.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295577539.md)
---

# SVRA: MOLBREEVI shows strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market

MOLBREEVI, an inhaled biologic for autoimmune PAP, demonstrated significant clinical benefits and a favorable safety profile in Phase 3 trials, addressing a high unmet need in a rare disease with no approved therapies. Regulatory filings are underway, with a potential U.S. market exceeding $2B and robust financial backing.

Original document: Savara, Inc. \[SVRA\] Slides Release — Aug. 11 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)

## Related News & Research

- [Savara merilis presentasi korporasi tentang penyakit paru langka autoimmune PAP dan kandidat terapi inhalasi MOLBREEVI](https://longbridge.com/en/news/295577813.md)
- [Savara posts corporate presentation focused on autoimmune pulmonary alveolar proteinosis and MOLBREEVI program](https://longbridge.com/en/news/292798258.md)
- [Iconovo enters strategic collaboration agreement with Lonza on spray-dried inhaled formulations](https://longbridge.com/en/news/296445004.md)
- [Does Verizon’s Pixel 11 Push and AI Partnerships Reshape the Bull Case For Verizon Communications (VZ)?](https://longbridge.com/en/news/296016377.md)
- [BFT: Double-digit EBIT growth, margin expansion, and strong cash flow drive robust 2Q26 results](https://longbridge.com/en/news/296514233.md)